Key clinical point: Both nivolumab and nivolumab plus ipilimumab were effective in patients with chemotherapy-refractory esophagogastric cancer.
Major finding: Treatment with nivolumab plus ipilimumab was associated with an objective response rate of 24%.
Study details: CheckMate-032 is an ongoing phase 1/2 trial involving 160 patients with metastatic or locally advanced chemotherapy-refractory esophageal, gastric, or gastroesophageal junction cancer from centers in Europe and the United States.
Disclosures: The study was supported by Bristol-Myers Squibb. The authors also reported funding from Merck, Incyte, Gilead Sciences, and others.
Janjigian YY et al. J Clin Oncol. 2018 Aug 15. doi: 10.1200/JCO.2017.76.6212.
This Week's Must Reads
Oncologists raise access concerns about new mobile technology, Article based on interviews.
Broad opioid legislation advances in Congress, Senate floor debate, Sept. 17, 2018
Early supportive care cuts costs related to curative treatment, Koprowski CD et al. 2018 ASCO Quality Care Symposium, Abstract 142
Employee deductibles outstrip wages, Kaiser Family Foundation, 2018 Employer Health Benefits
The financial burden of metastatic breast cancer, Wheeler SB et al. Quality Care Symposium, Abstract 32
Must Reads in Gastroenterology
Refractory esophagogastric cancer: Nivolumab plus ipilimumab ups response rate , Janjigian YY et al. J Clin Oncol. 2018 Aug 15. doi: 10.1200/JCO.2017.76.6212.
Study evaluates surveillance intervals after Barrett's esophagus ablation, Cotton CC et al. Gastroenterology. 2018 Apr 12. doi: 10.1053/j.gastro.2018.04.011.
Software boosts accuracy of colonoscopies, Tripathi PV et al. DDW 2018 (Digestive Disease Week, 2018). Presentation 133.
Colorectal cancer costs twice as much in US as Canada, Yezefski et al. ASCO 2018 Abstract LBA3579.
Fiber Intake and Survival After CRC Diagnosis, JAMA Oncol; ePub 2017 Nov 2; Song, Wu, et al